R01MD018523

A multilevel, multiphase optimization strategy for PREP: patients and providers in primary care - what we know: There are 1.2 million people in the US who meet the indications for PREP; yet, disparities exist in uptake. For example, only 9% of black and 16% of Latino individuals, compared to 65% of white individuals, have been prescribed PREP. At Henry Ford Health (HFH) System, only 10% of eligible patients have been prescribed PREP.

Primary care is an ideal setting for PREP to be offered as an HIV prevention method since providers see large numbers of patients who are HIV negative, with some who are at increased risk for HIV, and the primary care setting is often the point of entry to the healthcare system.

The multiphase optimization strategy (MOST) framework is a novel, innovative way to identify an efficient intervention.

What we will do: In this optimization trial, we will test the effectiveness of intervention components, alone and in combination, on new PREP prescriptions in primary care at HFH. First, we will generate feedback on context-specific (system and individual level) factors for intervention component delivery via focus groups with providers (N=15) and patients eligible for PREP (N=30). Then, we will test the four intervention components in an optimization trial, with 16 conditions being implemented at 32 clinics. Finally, we will generate feedback on the factors that affected implementation via semi-structured interviews with providers (N=30) and patients (N=30).

Participants will be primary care providers (PCPs) and patients eligible for PREP in Henry Ford Health System. Clinics will be randomized (yes/no) to receive any combination of provider and patient intervention components. Provider intervention components include computer-based simulation training and/or best practice alerts delivered via the electronic health record (EHR). Patient intervention components include HIV risk assessment and/or PREP informational video – both delivered via the EHR.

Primary outcome is the rate of new PREP prescriptions at the clinic level. Secondary outcomes will include PREP maintenance, number of HIV tests ordered by a PCP, and number of PCPs trained. Sub analyses will test which factors moderate (e.g., patient sex, race, age, gender, sexual orientation) or mediate (e.g., perceived HIV risk, provider and patient PREP knowledge) PREP uptake, focusing on priority populations and disparities in rates of PREP prescription.

Implications: 1) Understanding which intervention components lead to increased PREP prescriptions will represent an important advance in HIV prevention efforts. 2) Optimizing a multi-level intervention for providers and patients to increase PREP prescriptions would lead to a new, efficient, evidence-based option. 3) Determining what factors are related to PREP uptake will help reduce disparities in PREP initiation among those most in need. 4) Understanding the context specific factors related to intervention component implementation will help identify best methods for replication/adaptation in other healthcare systems.

In sum, our team brings a novel, innovative approach, robust interdisciplinary experience, strong preliminary work in HIV, PREP, MOST, and primary care, and scientific rigor to make a significant impact on the field.

Michigan State University

NOT APPLICABLE

93.307 - Minority Health and Health Disparities Research

National Institute for Minority Health and Health Disparities (NIMHD) [HHS - NIH]

East Lansing, Michigan 488242600 United States

Single Zip Code

Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection (R01 Clinical Trial Optional) (RFA-MD-23-008)

Termination This project grant was reported on the Department of Government Efficiency (DOGE) partial or complete termation list as of its last report October 2025. See All
Amendment Since initial award the End Date has been extended from 03/31/28 to 06/30/28 and the total obligations have increased 284% from $796,636 to $3,059,978.